These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31985399)

  • 1. Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism.
    Lane JR; Abramyan AM; Adhikari P; Keen AC; Lee KH; Sanchez J; Verma RK; Lim HD; Yano H; Javitch JA; Shi L
    Elife; 2020 Jan; 9():. PubMed ID: 31985399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist.
    Chien EY; Liu W; Zhao Q; Katritch V; Han GW; Hanson MA; Shi L; Newman AH; Javitch JA; Cherezov V; Stevens RC
    Science; 2010 Nov; 330(6007):1091-5. PubMed ID: 21097933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors.
    Michino M; Free RB; Doyle TB; Sibley DR; Shi L
    Chem Commun (Camb); 2015 May; 51(41):8618-21. PubMed ID: 25896577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Binding Geometries for Risperidone in Dopamine D3 Receptors: Insights on the Fast-Off Mechanism through Docking, Quantum Biochemistry, and Molecular Dynamics Simulations.
    Zanatta G; Della Flora Nunes G; Bezerra EM; da Costa RF; Martins A; Caetano EW; Freire VN; Gottfried C
    ACS Chem Neurosci; 2016 Oct; 7(10):1331-1347. PubMed ID: 27434874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-target dopamine D3 receptor modulators: Actionable knowledge for drug design from molecular dynamics and machine learning.
    Ferraro M; Decherchi S; De Simone A; Recanatini M; Cavalli A; Bottegoni G
    Eur J Med Chem; 2020 Feb; 188():111975. PubMed ID: 31940507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D
    Shaik AB; Boateng CA; Battiti FO; Bonifazi A; Cao J; Chen L; Chitsazi R; Ravi S; Lee KH; Shi L; Newman AH
    J Med Chem; 2021 Oct; 64(20):15313-15333. PubMed ID: 34636551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L
    J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling Activation-Related Rearrangements and Intrinsic Divergence from Ligand-Specific Conformational Changes of the Dopamine D3 and D2 Receptors.
    Lee KH; Shi L
    J Chem Inf Model; 2024 Mar; 64(6):1778-1793. PubMed ID: 38454785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectivity and activation of dopamine D3R from molecular dynamics.
    Feng Z; Hou T; Li Y
    J Mol Model; 2012 Dec; 18(12):5051-63. PubMed ID: 22752545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes.
    Hayatshahi HS; Luedtke RR; Taylor M; Chen PJ; Blass BE; Liu J
    J Chem Inf Model; 2021 Jun; 61(6):2829-2843. PubMed ID: 33988991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone.
    Wang S; Che T; Levit A; Shoichet BK; Wacker D; Roth BL
    Nature; 2018 Mar; 555(7695):269-273. PubMed ID: 29466326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of key receptor-ligand interactions of dopaminergic arylpiperazines and the dopamine D2 receptor homology model.
    Sukalovic V; Soskic V; Sencanski M; Andric D; Kostic-Rajacic S
    J Mol Model; 2013 Apr; 19(4):1751-62. PubMed ID: 23300056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RalA employs GRK2 and β-arrestins for the filamin A-mediated regulation of trafficking and signaling of dopamine D2 and D3 receptor.
    Zheng M; Zhang X; Sun N; Min C; Zhang X; Kim KM
    Biochim Biophys Acta; 2016 Aug; 1863(8):2072-83. PubMed ID: 27188791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
    Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the structural prediction of G protein-coupled receptors: D3 receptor in complex with eticlopride.
    Obiol-Pardo C; López L; Pastor M; Selent J
    Proteins; 2011 Jun; 79(6):1695-703. PubMed ID: 21491496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.
    Verma RK; Abramyan AM; Michino M; Free RB; Sibley DR; Javitch JA; Lane JR; Shi L
    PLoS Comput Biol; 2018 Jan; 14(1):e1005948. PubMed ID: 29337986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs.
    Ferruz N; Doerr S; Vanase-Frawley MA; Zou Y; Chen X; Marr ES; Nelson RT; Kormos BL; Wager TT; Hou X; Villalobos A; Sciabola S; De Fabritiis G
    Sci Rep; 2018 Jan; 8(1):897. PubMed ID: 29343833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.